Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop study reveals how fluid drains in healthy eyes

NCT ID NCT05938699

Knowledge-focused Sponsor: Nicox Ophthalmics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study tested NCX 470 eye drops in 18 healthy adults to see how they change fluid dynamics inside the eye. Participants received either the active drop or a placebo for 8 days. The goal was to measure fluid production, drainage, and pressure. Results will help researchers understand how this treatment might work for glaucoma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NCX 470 (nitric oxide-donating bimatoprost) eye drops
What this could lead to
If successful, this study could explain exactly how NCX 470 lowers eye pressure, supporting its development as a treatment for open-angle glaucoma.
What could go wrong
This was a small, early-stage study in healthy volunteers, not glaucoma patients. The results may not predict real-world effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

18 people

The number who actually took part.

Started

Dec 2023

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥18 years of age 2. Either gender 3. Subjects without glaucoma 4. Qualifying IOP at Screening Visit Exclusion Criteria: 1. Narrow anterior chamber angles or disqualifying central corneal thickness in either eye 2. Clinically significant ocular disease in either eye 3. Uncontrolled systemic disease 4. Serious hypersensitivity to topical anesthetic eye drops 5. Subjects with a known hypersensitivity or contraindications to any of the ingredients in the study medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open angle glaucoma

Contacts and locations

Locations

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.